JP2009523175A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009523175A5 JP2009523175A5 JP2008550493A JP2008550493A JP2009523175A5 JP 2009523175 A5 JP2009523175 A5 JP 2009523175A5 JP 2008550493 A JP2008550493 A JP 2008550493A JP 2008550493 A JP2008550493 A JP 2008550493A JP 2009523175 A5 JP2009523175 A5 JP 2009523175A5
- Authority
- JP
- Japan
- Prior art keywords
- zinc
- copper
- complex
- agent
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000010949 copper Substances 0.000 claims 35
- 229910052802 copper Inorganic materials 0.000 claims 35
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 34
- 239000011701 zinc Substances 0.000 claims 34
- 229910052725 zinc Inorganic materials 0.000 claims 34
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 31
- UHXXJVYBIFPFFQ-DKWTVANSSA-N (2r)-2-amino-3-sulfanylpropanoic acid;zinc Chemical compound [Zn].SC[C@H](N)C(O)=O UHXXJVYBIFPFFQ-DKWTVANSSA-N 0.000 claims 14
- 239000002738 chelating agent Substances 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 239000008188 pellet Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 10
- 239000003826 tablet Substances 0.000 claims 10
- 241001465754 Metazoa Species 0.000 claims 9
- 238000010521 absorption reaction Methods 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 239000002775 capsule Substances 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 239000006187 pill Substances 0.000 claims 8
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 6
- CXVCSRUYMINUSF-UHFFFAOYSA-N tetrathiomolybdate(2-) Chemical compound [S-][Mo]([S-])(=S)=S CXVCSRUYMINUSF-UHFFFAOYSA-N 0.000 claims 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 5
- 239000011724 folic acid Substances 0.000 claims 5
- 229960000304 folic acid Drugs 0.000 claims 5
- 235000019152 folic acid Nutrition 0.000 claims 5
- 230000003908 liver function Effects 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- 150000003751 zinc Chemical class 0.000 claims 5
- 241000282412 Homo Species 0.000 claims 4
- 235000018417 cysteine Nutrition 0.000 claims 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 235000018102 proteins Nutrition 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 210000002784 stomach Anatomy 0.000 claims 4
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims 3
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000002702 enteric coating Substances 0.000 claims 3
- 238000009505 enteric coating Methods 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 229960001639 penicillamine Drugs 0.000 claims 3
- 229960001124 trientine Drugs 0.000 claims 3
- 239000004246 zinc acetate Substances 0.000 claims 3
- -1 zinc salt amino acid Chemical class 0.000 claims 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 2
- 229920002126 Acrylic acid copolymer Polymers 0.000 claims 2
- 208000031295 Animal disease Diseases 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 108090000157 Metallothionein Proteins 0.000 claims 2
- 102000003792 Metallothionein Human genes 0.000 claims 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 2
- 229920002125 Sokalan® Polymers 0.000 claims 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 239000003529 anticholesteremic agent Substances 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 229920002301 cellulose acetate Polymers 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 239000008139 complexing agent Substances 0.000 claims 2
- 150000004699 copper complex Chemical class 0.000 claims 2
- 230000001934 delay Effects 0.000 claims 2
- 239000003405 delayed action preparation Substances 0.000 claims 2
- 235000013305 food Nutrition 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims 1
- VSKCCZIUZNTICH-ZPYUXNTASA-N (e)-but-2-enoic acid;ethenyl acetate Chemical compound C\C=C\C(O)=O.CC(=O)OC=C VSKCCZIUZNTICH-ZPYUXNTASA-N 0.000 claims 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- 108010075016 Ceruloplasmin Proteins 0.000 claims 1
- 102100023321 Ceruloplasmin Human genes 0.000 claims 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 229920003134 Eudragit® polymer Polymers 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 229920001800 Shellac Polymers 0.000 claims 1
- 229920002807 Thiomer Polymers 0.000 claims 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 claims 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 claims 1
- 239000011609 ammonium molybdate Substances 0.000 claims 1
- 235000018660 ammonium molybdate Nutrition 0.000 claims 1
- 229940010552 ammonium molybdate Drugs 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 229940127226 anticholesterol agent Drugs 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 claims 1
- 239000000227 bioadhesive Substances 0.000 claims 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 229960004106 citric acid Drugs 0.000 claims 1
- 229960005228 clioquinol Drugs 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000013034 coating degradation Methods 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 claims 1
- 229960001489 deferasirox Drugs 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 239000005038 ethylene vinyl acetate Substances 0.000 claims 1
- 210000005095 gastrointestinal system Anatomy 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000001630 jejunum Anatomy 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940068041 phytic acid Drugs 0.000 claims 1
- 239000000467 phytic acid Substances 0.000 claims 1
- 235000002949 phytic acid Nutrition 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 210000001187 pylorus Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000004208 shellac Substances 0.000 claims 1
- 229940113147 shellac Drugs 0.000 claims 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 1
- 235000013874 shellac Nutrition 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 125000005591 trimellitate group Chemical group 0.000 claims 1
- 229920006163 vinyl copolymer Polymers 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 239000011667 zinc carbonate Substances 0.000 claims 1
- 235000004416 zinc carbonate Nutrition 0.000 claims 1
- 229910000010 zinc carbonate Inorganic materials 0.000 claims 1
- 239000011592 zinc chloride Substances 0.000 claims 1
- 235000005074 zinc chloride Nutrition 0.000 claims 1
- 239000011670 zinc gluconate Substances 0.000 claims 1
- 235000011478 zinc gluconate Nutrition 0.000 claims 1
- 229960000306 zinc gluconate Drugs 0.000 claims 1
- 239000011787 zinc oxide Substances 0.000 claims 1
- 235000014692 zinc oxide Nutrition 0.000 claims 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims 1
- 229960001763 zinc sulfate Drugs 0.000 claims 1
- 229910000368 zinc sulfate Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75767206P | 2006-01-10 | 2006-01-10 | |
| US76581206P | 2006-02-07 | 2006-02-07 | |
| PCT/US2007/060345 WO2007084818A2 (en) | 2006-01-10 | 2007-01-10 | Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009523175A JP2009523175A (ja) | 2009-06-18 |
| JP2009523175A5 true JP2009523175A5 (enExample) | 2010-02-25 |
Family
ID=38288339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008550493A Pending JP2009523175A (ja) | 2006-01-10 | 2007-01-10 | 目標とされる安定な銅状態を達成及び維持して銅関連中枢神経系疾患を予防及び治療するための医薬組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070207191A1 (enExample) |
| EP (1) | EP1993607A4 (enExample) |
| JP (1) | JP2009523175A (enExample) |
| AU (1) | AU2007205996A1 (enExample) |
| CA (1) | CA2675230A1 (enExample) |
| WO (1) | WO2007084818A2 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7164035B2 (en) | 2000-01-07 | 2007-01-16 | Newsome David A | Zinc-monocysteine complex and method of using zinc-cysteine complexes |
| JP5099620B2 (ja) * | 2006-10-26 | 2012-12-19 | 学校法人日本大学 | 筋萎縮性側索硬化症治療薬 |
| US8247398B2 (en) * | 2007-02-17 | 2012-08-21 | Ssv Therapeutics, Inc. | Zinc complexes of natural amino acids for treating elevated copper caused toxicities |
| KR20100015526A (ko) * | 2007-03-12 | 2010-02-12 | 피펙스 파마슈티컬스, 인코포레이티드 | 유리 구리 흡수 및 유리 구리 수준을 안전하게 낮추는데 유용한 경구용 아연 의약 |
| GB2450117A (en) * | 2007-06-13 | 2008-12-17 | Reckitt Benckiser Healthcare | A water- and oxygen-occlusive blister tablet pack |
| US20090028800A1 (en) * | 2007-07-27 | 2009-01-29 | Peeples William H | Method of Treating Postpartum Depression and Aggression |
| US8497122B2 (en) | 2008-04-11 | 2013-07-30 | Washington University | Biomarkers for Niemann-pick C disease and related disorders |
| EP2464350B1 (en) * | 2009-09-11 | 2016-08-24 | Nestec S.A. | Compositions and methods for enhancing cognitive and related functions in animals |
| US20110212189A1 (en) * | 2009-11-01 | 2011-09-01 | Adeona Pharmaceuticals, Inc. | Gastroretentive oral high dose zinc preparations |
| EP2578221A1 (en) * | 2011-10-04 | 2013-04-10 | Magnus Intellectual Property Ltd. | The therapeutic use of tetrathiomolybdate |
| US10478455B2 (en) | 2010-03-30 | 2019-11-19 | Ucl Business Ltd | Therapeutic use of tetrathiomolybdate |
| GB201005394D0 (en) * | 2010-03-30 | 2010-05-12 | Magnus Intellectual Property Ltd | Therapy |
| MX2013004123A (es) | 2010-10-12 | 2013-12-16 | Univ Johns Hopkins | Composiciones antitusigenas que comprenden memantina. |
| WO2015100300A2 (en) * | 2013-12-23 | 2015-07-02 | Duke University | Methods for diagnosing and treating copper-dependent diseases |
| WO2015154897A1 (en) * | 2014-04-08 | 2015-10-15 | Wolfgang Stremmel | Means and methods for treating disorders of copper metabolism |
| US10583102B2 (en) | 2014-10-06 | 2020-03-10 | The Johns Hopkins University | Targeting liver nuclear receptors as a treatment for wilson disease |
| KR20160057500A (ko) * | 2014-11-05 | 2016-05-24 | 아카데미아 시니카 | 클리오퀴놀을 포함하는 자폐증 스펙트럼 장애의 치료용 약학적 조성물 |
| US20160220500A1 (en) * | 2014-11-14 | 2016-08-04 | Kent State University | Targeting Intracellular Copper Ions for Inhibiting Angiogenesis Using Nanoparticles of Ternary Inorganic Metal Sulfide M1M2S4 (M1, independently, is Mg, Ca, Mn, Fe, or Zn; M2 = Mo or W) Compounds to Treat Metastatic Cancer |
| US10226484B2 (en) | 2014-12-01 | 2019-03-12 | Peter Y Novak | Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof |
| US12527820B2 (en) | 2014-12-01 | 2026-01-20 | Vector Vitale Ip Llc | Pharmaceutical composition and method for suppressing degeneration |
| JP6716464B2 (ja) * | 2014-12-03 | 2020-07-01 | ノーベルファーマ株式会社 | 酢酸亜鉛水和物錠及びその製造方法 |
| CN107208105A (zh) * | 2014-12-17 | 2017-09-26 | 基础应用医学研究基金会 | 用于治疗威尔森病的核酸构建体和基因治疗载体 |
| ITUA20163931A1 (it) * | 2016-05-30 | 2017-11-30 | Biofordrug S R L | Miscele di caffé per la neuroprotezione |
| US10413570B2 (en) * | 2016-12-01 | 2019-09-17 | Daniel McCaughan | Method of manufacturing a zinc compound lozenge |
| CA3054201A1 (en) * | 2017-02-21 | 2018-08-30 | Fine Cotton Factory Inc. | Articles for treating concussion and other disorders |
| US10183041B2 (en) | 2017-04-12 | 2019-01-22 | Vector Vitale Ip Llc | Antibacterial composition and its use in treating bacterial infections |
| US11419832B2 (en) | 2017-12-04 | 2022-08-23 | Alexion Pharmaceuticals, Inc. | Bis-choline tetrathiomolybdate for treating Wilson Disease |
| EP3720433B1 (en) * | 2017-12-04 | 2022-02-02 | Alexion Pharmaceuticals, Inc. | Bis-choline tetrathiomolybdate for treating wilson disease |
| WO2019191270A1 (en) * | 2018-03-27 | 2019-10-03 | The Board Of Trustees Of The University Of Illinois | Restoration of transmembrane copper transport |
| AU2019300031B2 (en) * | 2018-07-12 | 2025-06-12 | The Texas A&M University System | Compositions for the treatment of copper deficiency and methods of use |
| CN114558029A (zh) * | 2019-01-16 | 2022-05-31 | 武汉广行科学研究有限公司 | 铜团簇、胸腺嘧啶修饰的透明质酸和多聚铜团簇、其制备方法和应用 |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| CN113840596A (zh) * | 2019-03-20 | 2021-12-24 | 林德拉治疗公司 | 用于胃滞留剂型的衣层 |
| IL286512B2 (en) | 2019-03-20 | 2026-03-01 | Lyndra Therapeutics Inc | Capsules and capsule coatings for stomach-retaining dosage forms |
| CN112138024A (zh) * | 2019-06-26 | 2020-12-29 | 里弗斯Pah有限责任公司 | 治疗严重形式的肺动脉高压的方法 |
| JP7311086B2 (ja) * | 2019-08-21 | 2023-07-19 | ブレイン ケミストリー ラブズ | 金属及びｌ－セリンを含む組成物、並びにその使用 |
| US11484610B2 (en) | 2019-11-22 | 2022-11-01 | Vector Vitale Ip Llc | Method of treating melanoma |
| US11596650B2 (en) | 2019-12-20 | 2023-03-07 | Vector Vitale Ip Llc | Composition and method for the treatment of type 2 diabetes |
| US10933091B1 (en) | 2019-12-20 | 2021-03-02 | Vector Vitale Ip Llc | Composition and method for the treatment of type I diabetes |
| US10799530B1 (en) | 2019-12-20 | 2020-10-13 | Vector Vitale Ip Llc | Composition and method for the prevention and treatment of obesity |
| JP7457827B2 (ja) * | 2020-03-16 | 2024-03-28 | 武漢広行科学研究有限公司 | 肝硬変の治療のための銅クラスター及び組成物 |
| GB2612210B (en) * | 2020-06-24 | 2025-08-27 | Reverspah Llc | Pharmaceutical composition comprising a tetrathiomolybdate salt and a diethylcarbamazine |
| EP4429653A4 (en) * | 2021-11-10 | 2025-10-29 | Reverspah Llc | CANCER TREATMENT PROCESSES AND COMPOSITIONS |
| KR102981946B1 (ko) * | 2023-04-27 | 2026-06-24 | 국립해양생물자원관 | 다중구리 산화효소 활성 도메인의 개량 펩타이드를 포함하는 구리대사 관련 신경계 질환의 예방 또는 치료용 조성물 |
| KR20250125186A (ko) * | 2024-02-14 | 2025-08-21 | 국립부경대학교 산학협력단 | 알부민 고정 셀룰로오스 및 이를 포함하는 알츠하이머 치료용 조성물 |
| CN118924916B (zh) * | 2024-05-22 | 2025-01-21 | 吉林医药学院 | 一种负载阿霉素的复合纳米粒子 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863898A (en) * | 1986-02-06 | 1989-09-05 | Albion International, Inc. | Amino acid chelated compositions for delivery to specific biological tissue sites |
| US5972328A (en) * | 1993-03-29 | 1999-10-26 | Queen's University At Kingston | Method for treating amyloidosis |
| ES2175676T3 (es) * | 1997-01-14 | 2002-11-16 | Lohmann Therapie Syst Lts | Sistema terapeutico expansible de retencion gastrica con liberacion controlada de principio activo en el tracto gastrointestinal. |
| GB9710699D0 (en) * | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
| ATE228375T1 (de) * | 1998-09-04 | 2002-12-15 | Univ Michigan | THIOMOLYBDAT VERBUNDEN MIT MINDESTENS EINEM KOHLENHYDRAT, UND SEINE VERWENDUNG ZUR VORBEUGUNG UND BEHANDLUNG VON ERKRANKUNGEN, DIE DURCH EINE ANORMALE VASKULARISIERUNG GEKENNZEICHNET SIND, WIE Z.B. KREBS, ßFEUCHTEß MAKULADEGENERATION, RHEUMATOIDE ARTHRITIS |
| US6797283B1 (en) * | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
| US6586611B1 (en) * | 2000-01-07 | 2003-07-01 | David A. Newsome | Zinc-monocysteine complex and method of using zinc-cysteine complexes |
| FR2811571B1 (fr) * | 2000-07-11 | 2002-10-11 | Flamel Tech Sa | Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif |
| US20020155170A1 (en) * | 2000-11-30 | 2002-10-24 | Walsh William John | Nutrient supplements and methods for treating autism and for preventing the onset of autism |
| US20030012824A1 (en) * | 2001-07-03 | 2003-01-16 | Ott Dana Beth | Orally administered anti-stress composition |
| EP2500018B1 (en) * | 2002-03-08 | 2017-07-19 | PhilERA New Zealand Limited | Preventing and/or Treating Cardiovascular Disease and/or Associated Heart Failure |
| US6855340B2 (en) * | 2002-05-24 | 2005-02-15 | Regents Of The University Of Michigan | Copper lowering treatment of inflammatory and fibrotic diseases |
| KR20050101537A (ko) * | 2002-12-24 | 2005-10-24 | 뉴로켐 (인터내셔널) 리미티드 | 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제 |
| US20040191295A1 (en) * | 2003-03-28 | 2004-09-30 | Locniskar Mary Frances | Composition and method for viral inhibition |
| US20060045865A1 (en) * | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| US8247398B2 (en) * | 2007-02-17 | 2012-08-21 | Ssv Therapeutics, Inc. | Zinc complexes of natural amino acids for treating elevated copper caused toxicities |
-
2007
- 2007-01-10 JP JP2008550493A patent/JP2009523175A/ja active Pending
- 2007-01-10 WO PCT/US2007/060345 patent/WO2007084818A2/en not_active Ceased
- 2007-01-10 AU AU2007205996A patent/AU2007205996A1/en not_active Abandoned
- 2007-01-10 EP EP07718298A patent/EP1993607A4/en not_active Withdrawn
- 2007-01-10 CA CA002675230A patent/CA2675230A1/en not_active Abandoned
- 2007-05-07 US US11/621,962 patent/US20070207191A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7335056B2 (ja) | ビグアナイド組成物および代謝障害を治療する方法 | |
| EP2785337B1 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
| JP5077903B2 (ja) | 相乗的鎮痛作用の得られるオピオイド鎮痛剤とシクロオキシゲナーゼ−２阻害剤との組合せ | |
| US20120178771A1 (en) | Oral Pharmaceutical Compositions of Buprenorphine and Method of Use | |
| ES2505257T3 (es) | Forma farmacéutica oral que comprende un sistema contra el uso incorrecto | |
| US20100152221A1 (en) | Pharmaceutical composition | |
| US20100093712A1 (en) | Two-component pharmaceutical composition for the treatment of pain | |
| CA2601289A1 (en) | Once-a-day oxycodone formulations | |
| EP2900230B1 (en) | Compounds for the treatment of obesity and methods of use thereof | |
| US11957686B2 (en) | Compositions for delivery of reboxetine | |
| EP3684418A1 (en) | Methods for the treatment of cysteamine sensitive disorders | |
| US9421200B1 (en) | Treating pain in patients with hepatic impairment | |
| JP2005528430A5 (enExample) | ||
| TW201408299A (zh) | 不含鹼化劑之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）調配物 | |
| MD3684344T2 (ro) | Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora | |
| JP2004507487A (ja) | 腸疾患治療薬 | |
| JP2007509146A5 (enExample) | ||
| WO2010023690A2 (en) | Prolonged release formulation of amisulpride | |
| AU2008338439A1 (en) | Pharmaceutical composition | |
| CN110381926A (zh) | 新型剂型 | |
| WO2010104494A1 (en) | Modified release pharmaceutical compositions of buprenorphine | |
| WO2013109316A1 (en) | Enteric-coated ht-2157 compositions and methods of their use | |
| US11458104B1 (en) | Enteric coated tiopronin tablet | |
| JP2022536494A (ja) | 下痢型過敏性腸症候群に関連する腹痛の処置 | |
| WO2024112955A1 (en) | Modified-release silodosin compositions and use thereof in methods for male contraception |